US 12,304,964 B2
CD38 modulating antibody
Anne Goubier, Stevenage (GB); Josephine Salimu, Stevenage (GB); Kevin Moulder, Stevenage (GB); Beatriz Goyenechea Corzo, Stevenage (GB); Simone Filosto, Stevenage (GB); Pascal Merchiers, Stevenage (GB); Nina Eissler, Stevenage (GB); Hemanta Baruah, Lebanon, NH (US); and Bianka Prinz, Lebanon, NH (US)
Assigned to BLACK BELT THERAPEUTICS LIMITED, Stevenage (GB)
Filed by BLACK BELT THERAPEUTICS LIMITED, Stevenage (GB)
Filed on Nov. 30, 2022, as Appl. No. 18/060,135.
Application 18/060,135 is a continuation of application No. 16/638,199, granted, now 11,542,338, previously published as PCT/EP2018/072271, filed on Aug. 16, 2018.
Application 16/638,199 is a continuation of application No. PCT/EP2018/065237, filed on Jun. 8, 2018.
Claims priority of provisional application 62/546,322, filed on Aug. 16, 2017.
Claims priority of provisional application 62/582,653, filed on Nov. 7, 2017.
Claims priority of provisional application 62/582,666, filed on Nov. 7, 2017.
Prior Publication US 2023/0089373 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C12N 1/00 (2006.01); C12N 15/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); A61K 39/395 (2013.01); A61K 2039/627 (2013.01); C07K 2317/565 (2013.01); C12N 1/00 (2013.01); C12N 15/00 (2013.01)] 16 Claims
 
1. An anti-CD38 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 12, and wherein the antibody or antigen-binding fragment thereof comprises a variable light chain sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 13, wherein the sequence variation occurs only in the framework regions.